Indian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lost Revlimid sales and pricing challenges. Lupin and Divi’s are poised for strong performance, with Sun Pharma and Torrent showing resilience. Apollo Hospitals expects robust traction across its diverse segments.
Paused your mutual fund SIP investments? Here’s how temporary interruptions can affect your financial goals
When investors think about financial mistakes, they usually quantify them in rupees. One common mistake is pausing SIPs for a temporary period and resuming them